Psychotropic medications and metabolic side effects in common genetic syndromes with intellectual disability-case report

Charanya Kaliamoorthy; Moushumi Purkayastha Mukherjee; Manul Das; Nivedhitha Selvakumar; Preeti Kandasamy

doi:10.30834/KJP.33.1.2020.193

Authors

Charanya Kaliamoorthy Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education & Research(JIPMER), Puducherry, India
Moushumi Purkayastha Mukherjee Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education & Research(JIPMER), Puducherry, India
Manul Das Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education & Research(JIPMER), Puducherry, India
Nivedhitha Selvakumar Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education & Research(JIPMER), Puducherry, India
Preeti Kandasamy Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education & Research(JIPMER), Puducherry, India

DOI:

https://doi.org/10.30834/KJP.33.1.2020.193

Keywords:

Genetic syndromes, Aripiprazole, Down syndrome, Prader-Willi syndrome, cardio-metabolic side-effect

Abstract

Multi-systemic genetic disorders are strongly associated with psychiatric illness and may require psychotropics for their management. The choice of psychotropics is primarily determined by medical comorbidities and adverse effects. A careful assessment of behavioural phenotype and metabolic monitoring for children on psychotropics should be followed to avoid adverse consequences. Hence, the need for monitoring of metabolic syndrome during routine clinical evaluation and the use of aripiprazole which demonstrated a good response with minimal adverse effects are highlighted with a description of cases of children with intellectual disability and neurodevelopmental genetic syndromes like Down Syndrome and Prader-Willi syndrome.

References

Trollor JN. Psychiatric disorders: management. In: Management guidelines: developmental disability. Version 3. Melbourne: Therapeutic Guidelines Limited; 2012.

Bull MJ; Committee on Genetics. Health supervision for children with Down syndrome. Paediatrics. 2011 Aug;128(2):393-406. doi: 10.1542/peds.2011-1605. Epub 2011 Jul 25.

Girimaji SC.Clinical practice guidelines for the diagnosis and management of children with Mental retardation. Indian Psychiatry Society, Clinical practice guidelines. 2008. 43-67.

Prasher VP. Overweight and obesity amongst Down’s syndrome adults. J Intellect Disabil Res 1995;39(Pt 5):437-41.

Fujiura GT, Fitzsimons N, Marks B, Chicoine B. Predictors of BMI among adults with Down syndrome: the social context of health promotion. Res Dev Disabil 1997;18:261-74.

Holland AJ. Behavioural phenotypes associated with specific genetic disorder: evidence from a population-based study of people with Prader-Willi syndrome. 2003;33(1):141-53.

Eiji Kirino. Efficacy and safety of aripiprazole in child and adolescent patients. Eur Child Adolesc Psychiatry. 2012 Jul; 21(7): 361–368.

Buono, S., Scannella, F., & Palmigiano, M. B. (2010). Self-injurious behaviour: A comparison between Prader-Willi syndrome, Down syndrome and Autism. Life Span and Disability, 13(2), 187-201.

Wolfgang Briegel. Clinical Usefulness of Aripiprazole Treatment in a Girl with Prader-Willi Syndrome and Psychosis. Clin Psychopharmacol Neurosci. 2018 Nov; 16(4): 497–500.

Reference: Gepstein V, Weiss R. Obesity as the Main Risk Factor for Metabolic Syndrome in Children. Front Endocrinol (Lausanne). 2019;10:568. Published 2019 Aug 16